Orchestra BioMed (OBIO) Insider Chris Cleary Buys 42,553 Shares

Chris Cleary made a significant move by purchasing 42,553 shares of OBIO on June 23, 2026. This insider transaction did not involve a pre-planned trading program, indicating a personal decision to increase his stake in the company. As of Friday, OBIO shares traded at $3.98.

Other Institutional Activity in OBIO

Several institutional investors have also made changes to their holdings in OBIO. RTW Investments, LP maintained its position with 8,306,063 shares valued at about $35.3 million. Perceptive Advisors LLC decreased its holdings by 89,350 shares, ending with 5,037,906 shares worth approximately $21.4 million, reflecting a 1.7% decrease. Meanwhile, Vanguard Capital Management LLC opened a new position with 2,204,319 shares valued at $9.4 million. Propel Bio Management, LLC also initiated a new stake, holding 896,701 shares valued at $3.8 million. Millennium Management LLC significantly increased its stake by 459,070 shares, resulting in a total of 702,543 shares valued at $3.0 million, marking a 188.6% increase.

Orchestra BioMed Holdings, Inc. Stock Down 34.5%

On Friday, OBIO's stock traded at $3.98. While specific financial metrics are not provided, the stock's recent activity indicates a dynamic market presence. Investors are closely watching institutional movements and insider transactions to gauge potential future performance.

Insider Buying and Selling at Orchestra BioMed Holdings, Inc.

In addition to Chris Cleary's purchase, several insiders were active around the same time. Eric Fain bought 17,327 shares on June 23, 2026, while Jason Aryeh also acquired 42,553 shares on the same day. On June 24, 2026, a few insiders, including Cleary himself, sold shares in smaller amounts, suggesting varied strategic decisions among company executives.

Analysts Set New Price Targets

Analysts have been optimistic about OBIO, with several maintaining buy ratings. On May 19, 2026, B. Riley Securities maintained a buy rating with a $10 price target. HC Wainwright & Co. reiterated its buy stance with the same target on May 14, 2026. Barclays has consistently maintained a buy rating with targets ranging from $11 to $13, as seen in their latest update on May 13, 2026. Chardan Capital has been particularly bullish, maintaining a $20 target as of March 12, 2026.

Bottom Line

Chris Cleary's recent purchase of OBIO shares underscores his confidence in the company's future. Institutional investors and analysts appear to share this optimism, with several firms maintaining or initiating new positions and setting positive price targets. As these transactions and ratings reflect past actions and sentiments, investors should continue to monitor OBIO's performance and future disclosures for a more comprehensive view.